/
CDXS
$2.33-$0.06 (-2.51%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$217.2M
91M shares
52-week range
$0.96 – $3.87
47% from low
Sector
INDUSTRIAL ORGANIC CHEMICALS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-20.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $60.6M | $68.5M | $69.1M | $104.8M | $138.6M | $70.1M | $59.3M | $70.4M |
| Cost of revenue | $12.6M | $15.6M | $13.7M | $22.2M | $38.0M | $12.8M | $16.3M | $9.3M |
| Gross profit | $48.0M | $52.8M | $55.3M | $82.5M | $100.6M | $57.3M | $43.1M | $61.0M |
| Gross margin | 79.2% | 77.2% | 80.1% | 78.8% | 72.6% | 81.7% | 72.6% | 86.7% |
| R&D | $30.0M | $33.9M | $44.2M | $55.9M | $80.1M | $58.9M | $46.3M | $52.3M |
| Operating income | −$11.3M | −$12.5M | −$23.9M | −$22.7M | −$34.9M | −$68.1M | −$58.5M | −$38.3M |
| EBITDA | −$10.1M | −$8.0M | −$19.4M | −$15.1M | −$26.3M | −$49.3M | −$53.4M | −$33.9M |
| Net income | −$10.9M | −$11.9M | −$24.0M | −$21.3M | −$33.6M | −$76.2M | −$65.3M | −$44.0M |
| Net margin | -18.0% | -17.4% | -34.8% | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% |
| EPS (diluted) | -0.21 | -0.21 | -0.40 | -0.33 | -0.51 | -1.12 | -0.89 | -0.50 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $74M | $-0.37 | $-0.38–$-0.36 | 3 |
| 2027 | $89M | $-0.29 | $-0.46–$-0.12 | 2 |
| 2028 | $120M | $-0.01 | $-0.26–$0.25 | 2 |
| 2029 | $144M | $0.15 | $0.14–$0.17 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Codexis, Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
www.codexis.com- Employees
- 146
- IPO / List date
- Apr 22, 2010
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds CDXS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 198,733 | $323.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CDXS yet.
